We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Section A: Pre-market registration applications referred for advice
At this meeting, the committee’s advice was sought on 2 applications under evaluation by the TGA. The applications included:
| Active ingredient (TRADENAME) | Sponsor | Therapeutic area |
|---|---|---|
| Type C (extension of indications) | ||
| remdesivir (VEKLURY) | Gilead Sciences Pty Ltd | For treatment of COVID-19 |
*These application types are published on Prescription medicines: applications under evaluation.
In addition to:
- One seeking a major variation (change in dosage)
Further details of the ACM discussion and advice associated with these items may be released within the Australian Public Assessment Reports (AusPARs). Please note that there is a delay from when an application was considered at ACM and the publication of the AusPAR. Browse all AusPARs.
Further information
For further information visit the Advisory Committee on Medicines or contact the ACM Secretary by email: ACM@health.gov.au.